Genmab chief on sclerosis drug launch: Novartis prioritizes us
While Genmab's partner Novartis can start launching sclerosis drug Kesimpta in Europe after receiving EU authorization, the process is well underway in the US – and it's going well, according to CEO Jan van de Winkel.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.